Actively Recruiting
Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder
Led by Anders Fink-Jensen, MD, DMSci · Updated on 2026-05-14
100
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The HASHTAG Study is investigating whether the medicine semaglutide can help adults with cannabis use disorder (CUD) reduce their cannabis use. Participants will be randomly assigned to receive either semaglutide or a placebo. The first 50 participants will have functional brain scans (fMRI) to investigate how the brain responds to cannabis-related cues. The main outcome after 20 weeks is whether semaglutide reduces cannabis use compared to placebo. Changes in brain activity in response to cannabis cues will be explored as a secondary outcome.
CONDITIONS
Official Title
Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Provided informed oral and written consent
- Diagnosed with cannabis use disorder according to DSM-5 or ICD-10
- Currently seeking to reduce or stop cannabis use
- Positive urine test for cannabinoids
- Body mass index (BMI) of 23 kg/m² or higher
- Aged between 18 and 70 years
- Used cannabis on at least 16 days in the past 28 days
- Consumed cannabis equivalent to at least 14 grams of THC in the past 28 days before baseline
- Able to follow study procedures and attend follow-up visits
You will not qualify if you...
- Current diagnosis of substance use disorder other than cannabis or tobacco
- Current or past severe psychiatric illness (schizophrenia, bipolar disorder, or other psychoses) within the last 5 years
- Suicide attempt or suicidal behavior within the past 5 years
- Severe neurological disorders including serious brain injury, stroke, or brain bleeding
- Diagnosed with type 1 or type 2 diabetes
- Pregnant, breastfeeding, planning pregnancy within 8 months, or not using effective contraception if a woman of childbearing potential
- Impaired liver function (liver enzymes more than 3 times normal)
- Impaired kidney function (eGFR less than 50 ml/min or high plasma creatinine)
- Past or current severe pancreatic problems
- Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2
- Heart disease including severe heart failure, unstable angina, or recent heart attack
- Uncontrolled high blood pressure above specified limits
- Use of experimental medication in the past 30 days
- Use of weight-loss medication in the past 3 months
- Allergy to semaglutide or its ingredients
- For brain scan participants: contraindications to MRI such as metal implants or claustrophobia
- Unable to understand or speak Danish
- Any other condition that may affect participation as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Psychiatric Center Copenhagen, Frederiksberg Hospital
Frederiksberg, Denmark, 2100
Actively Recruiting
Research Team
M
Maria E Marstrand, MD
CONTACT
A
Anders Fink-Jensen, MD, DMSc
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here